WHO Pharmaceuticals Newsletter No. 1, 2016

 

OMS, 16 de febrero de 2016

 

Regulatory Matters

 

Amlodipine besilate............................................................................... 5

 

Antiretroviral medicines ...................................................................... ..5

 

Atovaquone ........................................................................................... 5

 

Azilsartan .............................................................................................. 6

 

Benzoyl peroxide and salicylic acid topical products ............................ 6

 

Bisphosphonates ................................................................................... 6

 

Deferasirox ........................................................................................... 7

 

Elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate and

 

anti-epileptic medications ....................................................................... 7

 

Fluoroquinolones oral antibiotics ............................................................ 7

 

Fomepizole ............................................................................................. 8

 

Fingolimod............................................................................................... 8

 

Interferon beta-1a .................................................................................. 8

 

Itraconazole ............................................................................................ 9

 

Lenvatinib ................................................................................................ 9

 

Levonorgestrel intrauterine contraceptive device (IUCD) ....................... 9

 

Mycophenolate mofetil ......................................................................... 10

 

Nintedanib ethanesulfonate .................................................................. 10

 

Nivolumab ............................................................................................. 10

 

Ombitasvir hydrate/paritaprevir hydrate/ritonavir ................................ 10

 

Peginterferon alfa-2a ...........................................................................  11

 

Piperacillin sodium ..................................................................................11

 

Posaconazole .........................................................................................11

 

Repaglinide and clopidogrel ...................................................................12

 

Sodium glucose co-transporter 2 (SGLT2) inhibitors ............................12

 

Thalidomide ........................................................................................... 12

 

Varenicline and alcohol........................................................................... 13

 

 

Safety of Medicines

 

Allopurinol ......................................................................................14

 

Bevacizumab ...................................................................................14

 

Codeine........................................................................................... 14

 

Finasteride ......................................................................................15

 

Melatonin ........................................................................................15

 

Pazopanib ....................................................................................... 15

 

Proton pump inhibitors ................................................................... 16

 

Rosiglitazone .................................................................................. 16

 

 

Signal

 

Vemurafenib and Atrial fibrillation: Signal strengthening ................17

 

 

Feature

 

Recommendations from the 38th Annual Meeting of Representatives of

 

the National Pharmacovigilance Centres participating in the WHO

 

Programme for International Drug Monitoring .................................. 24

 

 

Número completo disponible en http://bit.ly/1ot1ynd